SB-121 is under clinical development by Scioto Biosciences and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SB-121’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SB-121 overview

SB-121 is under development for the treatment of pervasive developmental disorder (PDD), childhood obesity, Clostridium difficile infections, necrotizing enterocolitis, sepsis, gut dysbiosis, neurology and metabolic disorders. The therapy is a biofilm of Lactobacillus reuteri, which is being developed based on activated bacterial therapeutics (ABT) delivery platform technology.

Scioto Biosciences overview

Scioto Biosciences is a preclinical stage biotech company that focused on the activation of beneficial bacteria that have the potential to advance healing for various diseases associated with the GI tract, Oncology, and CNS indications. Scioto Biosciences is headquartered in Indianapolis, Indiana, the US.

For a complete picture of SB-121’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.